| News
The DayOne Accelerator, in its 3rd year, is now accepting applications
02.10.2020
We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!
If you are a digital health entrepreneur that wants to gain feedback on your innovation, build connections across the healthcare ecosystem and potentially win a place in the DayOne Accelerator, then you are in the right place. The accelerator will again help you to develop your digital health venture together with one of Europe’s leading ecosystems with coaching, space and potential funding. The first step to send in your application before the 23.10.20 deadline. We will let you know by 05.11.2020 whether you are shortlisted for the accelerator program and therefore invited to in the DayOne Open Innovation Session
This year the accelerator will have three categories: Patient Centric Innovation, Diabetes & Metabolism, and Value Based Healthcare. For more information about the categories, full list of winner benefits, list of previous winners and more, visit the DayOne Accelerator page.
Don’t forget to apply before the 23.10.20 deadline, and feel free to send those in your network who could also be interested in participating; after all, we do love collaboration at DayOne.

Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
KUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read More